The NanoBiotechnology Group is mainly focused on the use of bioactive molecules and nanoparticles for the detection and treatment of different diseases, including Uveal and Cutaneous Melanoma, Pancreatic Cancer, and Duchenne Muscular Dystrophy, among others.

The group is rather multidisciplinary, with researchers from different disciplines, such as chemists, biologists, and pharmacists.

The main research topics are the following:

• Preparation of modified oligonucleotides for therapeutic and diagnosis applications.
• Preparation and modification of nanoparticles based on gold, iron oxide, and albumin for the delivery of drugs and nucleic acids.
• Development of nanosensors for multiple diseases, such as Uveal, Melanoma, Pancreatic cancer, COVID, HPV, or Duchenne Muscular Dystrophy.

Instituto Madrileño de Estudios Avanzados en Nanociencia (IMDEA Nanociencia), Cantoblanco, 28049 Madrid, Spain & CNB-CSIC-IMDEA Nanociencia Associated Unit “Unidad de Nanobiotecnología”.

IMDEA Nanociencia acknowledges support from the ‘Severo Ochoa’ Programme for Centres of Excellence in R&D (MINECO, Grant SEV-2016-0686)